Drugs.com - Clinical Trials Clinical trial news from Drugs.com. Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
-
Leucid Bio Granted MHRA Clinical Trial Authorisation for Lateral NKG2D CAR-T Cell Therapy LEU011
on September 21, 2023 at 11:09 am
LONDON, Sept. 21, 2023 . Leucid Bio ("Leucid" or the "Company"), a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company's proprietary Lateral CAR platform,...
-
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis
on September 21, 2023 at 12:09 am
LOS ANGELES, Sept. 21, 2023 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced today...
-
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder
on September 20, 2023 at 8:09 pm
CORAL GABLES, Fla., Sept. 20, 2023, Relmada Therapeutics, Inc., a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced efficacy results for the de novo (or new to treatment) patients (204...
-
Researchers Develop New Method to Identify Potential Stroke Therapies
on September 20, 2023 at 1:09 am
September 20, 2023 -- Researchers have identified uric acid as a potential therapy to enhance recovery from acute ischemic stroke using a new method for conducting preclinical animal research. In the study, researchers from the National Institutes...
-
Researchers Discover Biomarker for Tracking Depression Recovery
on September 20, 2023 at 12:09 am
September 20, 2023 -- Using a novel deep brain stimulation (DBS) device capable of recording brain signals, researchers have identified a pattern of brain activity or “biomarker” related to clinical signs of recovery from...
-
Clinical Trial of HIV Vaccine Begins in United States and South Africa
on September 20, 2023 at 12:09 am
September 20, 2023 -- A trial of a preventive HIV vaccine candidate has begun enrollment in the United States and South Africa. The Phase 1 trial will evaluate a novel vaccine known as VIR-1388 for its safety and ability to induce an HIV-specific...
-
Higher Buprenorphine Doses Associated with Improved Retention in Treatment for Opioid Use Disorder
on September 18, 2023 at 9:09 pm
NIH-funded study suggests need to reevaluate opioid addiction treatment recommendations in the era of fentanyl. September 18, 2023 -- Individuals with opioid use disorder who were prescribed a lower buprenorphine dose were 20% more likely to...
-
Peer-Reviewed Publication of Positive Preclinical Data of SiSaf’s SIS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis
on September 18, 2023 at 7:09 pm
GUILDFORD, United Kingdom, Sept. 18, 2023. SiSaf Ltd, an RNA therapeutics company, is pleased to announce the publication in the peer-reviewed journal Molecular Therapy Nucleic Acids(1) of positive in vivo data demonstrating the safety and efficacy...
-
Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma
on September 18, 2023 at 6:09 am
KT-333 Phase 1 oncology trial ongoing with an update including initial evaluation of its clinical antitumor activity in patients expected in the fourth quarter of 2023 Fast Track designation can potentially accelerate KT-333’s development...
-
NRX Pharmaceuticals Announces Data Sharing Agreement Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Bipolar Depression
on September 16, 2023 at 6:09 am
RADNOR, Pa., Sept. 15, 2023. NRx Pharmaceuticals, Inc. ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it has signed a data sharing agreement with the study leadership of a randomized,...
-
NIH Clinical Trial of Universal Flu Vaccine Candidate FluMos-v2 Begins
on September 15, 2023 at 8:09 pm
September 15, 2023 -- Enrollment in a Phase 1 trial of a new investigational universal influenza vaccine candidate has begun at the National Institutes of Health’s Clinical Center in Bethesda, Maryland. The trial is sponsored by the National...
-
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH
on September 15, 2023 at 8:09 pm
BOSTON, Sept. 15, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced dosing of the first patient in its two-part, Phase 2a...
-
First Patient Dosed in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata
on September 13, 2023 at 3:09 pm
WALTHAM, Mass. and DUBLIN, Sept. 13, 2023. Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been...
-
Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors
on September 11, 2023 at 8:09 pm
SINGAPORE, Sept. 12, 2023. On September 9th, 2023, Biosyngen Pte Ltd announced that the U.S. FDA has cleared the Investigational New Drug (IND) application for Phase I/II clinical trial of BRL03 for the treatment of lung cancer, gastric cancer...
-
First Dose Cohort completed and Second Dose Cohort Opened for B-cell Non-Hodgkin Lymphoma Phase 1 Clinical Trial of PMB-CT01
on September 11, 2023 at 6:09 am
IRVINE, Calif., Sept. 11, 2023. PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the first dose cohort of its phase 1 relapsed or refractory B-cell...
-
ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa
on September 11, 2023 at 5:09 am
The primary endpoint of HiSCR75 at week 16 did not meet statistical significance in the Non-Responder Imputation (NRI) primary analysis. HiSCR75 did meet statistical significance at week 16 in a Last Observation Carried Forward sensitivity...
-
Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis
on September 11, 2023 at 2:09 am
Topline Results for TAK-279 Show that a Significantly Greater Proportion of Psoriatic Arthritis Patients Achieved at Least an ACR20 Response Compared to Placebo at Week 121 Based on the Positive Results, Takeda Intends to Initiate a Phase 3 Study...
-
Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)
on September 11, 2023 at 2:09 am
RAHWAY, N.J.--(BUSINESS WIRE) September 11, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new analyses from studies of sotatercept, Merck’s novel investigational activin signaling inhibitor...
-
ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa
on September 11, 2023 at 12:09 am
The primary endpoint of HiSCR75 at week 16 did not meet statistical significance in the Non-Responder Imputation (NRI) primary analysis. HiSCR75 did meet statistical significance at week 16 in a Last Observation Carried Forward sensitivity...
-
Supernus Announces New Qelbree Data Showing Improvement in ADHD Symptom
on September 10, 2023 at 7:09 am
ROCKVILLE, Md., Sept. 09, 2023. Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announces the presentation of two posters at...